The effects of combined therapy for hypertension on arterial function

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1091220034

Enrollment

Registered

2010-01-12

Start date

2010-01-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension, type 2 diabetes mellitus

Interventions

Intervention type:DRUG Name of intervention:8mg candesartan plus 5mg amlodipine (comb1),12mg candesartanplus 2.5mg amlodipine (comb2) Dose form / Japanese Medical Device Nomenclature:TABLET,TABLET Rou

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Male and female patients with hypertension and type 2 diabetes, aged 20~80

Exclusion criteria

Exclusion criteria: intolerance of the drugs (candesartan and amlodipine)

Design outcomes

Primary

Measure	Time frame
serum levels of high sensitive C reactive protein, interleukin-6, soluble ICAM-1, and soluble VCAM-1	—

Secondary

Measure	Time frame
serum lipid concentrations, ABI, pulse wave velocity	—

Countries

Japan

Contacts

Public ContactMasumi Ai

Tokyo Medical and Dental University

ai.bec@tmd.ac.jp+81-3-5803-4724

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026